Varicella zoster infection in renal transplant recipients: Prevalence, complications and outcome

Kidney and Blood Pressure Research

Volumn 34, Issue 6, 2011, Pages 382-386

  Mustapic, Z ^a   Basic Jukic, Nikolina ^a   Kes, P ^a   Lovcic, V ^a   Bubic Filipi, Lj ^a   Mokos, I ^a   Kastelan, Z ^a   Zekan, S ^b  

^a KBC Zagreb   (Croatia)

^b Croatia   (Croatia)

Author keywords

Immunosuppression; Mycophenolate mofetil; Renal transplantation; Varicella zoster; Varicella zoster virus infection

Indexed keywords

ACICLOVIR; AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN A; DACLIZUMAB; GANCICLOVIR; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS; VARICELLA ZOSTER VACCINE;

ACTIVE IMMUNIZATION; ADULT; AGED; ARTICLE; CHICKENPOX; CLINICAL FEATURE; CYTOMEGALOVIRUS INFECTION; DERMATOME; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; FEMALE; GRAFT RECIPIENT; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEUROPATHY; POSTOPERATIVE PERIOD; PREVALENCE; PRIORITY JOURNAL; SKIN SCAR; TREATMENT DURATION;

ADULT; AGED; FEMALE; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PREVALENCE; TREATMENT OUTCOME;

EID: 79957934160     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000328730     Document Type: Article

References (25)

1. Fishman JA: Infection in renal transplant recipients. Semin Nephrol 2007; 27: 445-461.
2. Fehr T, Bossart W, Wahl C, Binswanger U: Disseminated varicella infection in adult renal allograft recipients: Four cases and a review of the literature. Transplantation 2002; 73: 608-611.
3. Rodriguez-Moreno A, Sanchez-Fructuoso AI, Calvo N, Ridao N, Conesa J, Marques M, Prats D, Barrientos A: Varicella infection in adult renal allograft recipients: Experience at one center. Transplant Proc 2006; 38: 2416-2418.
4. Lauzurica R, Bayés B, Frías C, Fontseré N, Hernandez A, Matas L, Jimenez A, Bonet J, Romero R: Disseminated varicella infection in adult renal allograft recipients: Role of mycophenolate mofetil. Transplant Proc 2003; 35: 1758-1759.
5. Gourishankar S, McDermid JC, Jhangri GS, Preiksaitis JK: Herpes zoster infection following solid organ transplantation: Incidence, risk factors and outcomes in the current immunosuppressive era. Am J Transplant 2004; 4: 108-115.
6. Miller GG, Dummer JS: Herpes simplex and varicella zoster viruses: Forgotten but not gone. Am J Transplant 2007; 7: 741-747.
7. Arness T, Pedersen R, Dierkhising R, Kremers W, Patel R: Varicella zoster virus-associated disease in adult kidney transplant recipients: Incidence and risk-factor analysis. Transpl Infect Dis 2008; 10: 260-268.
8. Fishman JA: Infection in solid-organ transplant recipients. N Engl J Med 2007; 57: 2601-2614.
9. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group: A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029-1037.
10. European Mycophenolate Mofetil Cooperative Study Group: Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321-1325.
11. Basic-Jukic N, Kes P, Bubic-Filipi LJ, Puretic Z, Brunetta B, Pasini J: Does mycophenolate mofetil increase the incidence of cytomegalovirus disease compared with azathioprine after cadaveric kidney transplantation? Transplant Proc 2005; 37: 850-851.
12. Basic-Jukic N, Racki S, Kes P, Mustapic Z: Cytomegalovirus infection in renal transplant recipients (in Croatian). Acta Med Croatica 2008; 62: 69-75.
13. Marcén R: Immunosuppressive drugs in kidney transplantation: Impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs 2009; 69: 2227-2243.
14. Satoh S, Tada H, Murakami M, Tsuchiya N, Inoue T, Togashi H, Matsuura S, Hayase Y, Suzuki T, Habuchi T: The influence of mycophenolate mofetil versus azathioprine and mycophenolic acid pharmacokinetics on the incidence of acute rejection and infectious complications after renal transplantation. Transplant Proc 2005; 37: 1751-1753.
15. Rothwell WS, Gloor JM, Morgenstern BZ, Milliner DS: Disseminated varicella infection in pediatric renal transplant recipients treated with mycophenolate mofetil. Transplantation 1999; 68: 158-161.
16. Buell C, Koo J: Long-term safety of mycophenolate mofetil and cyclosporine: A review. J Drugs Dermatol 2008; 7: 741-748.
17. Cox VC, Ensom MH: Mycophenolate mofetil for solid organ transplantation: Does the evidence support the need for clinical pharmacokinetic monitoring? Ther Drug Monit 2003; 25: 137-157.
18. Gnann JW: Other herpesviruses: Herpes simplex virus, varicella-zoster virus, human herpes types 6,7 and 8; in Transplant Infections, ed 1. Philadelphia, Lippincott-Raven, 1998, pp 265-286.
19. Gilden D, Cohrs RJ, Mahalingam R, Nagel MA: Varicella zoster virus vasculopathies: Diverse clinical manifestations, laboratory features, pathogenesis, and treatment. Lancet Neurol 2009; 8: 731-740.
20. Rogers SY, Irving W, Harris A, Russell NH: Visceral varicella zoster infection after bone marrow transplantation without skin involvement and the use of PCR for diagnosis. Bone Marrow Transplant 1995; 15: 805-807.
21. Jantsch J, Schmidt B, Bardutzky J, Bogdan C, Eckardt KU, Raff U: Lethal varicella-zoster virus reactivation without skin lesions following renal transplantation. Nephrol Dial Transplant 2011; 26: 365-368.
22. Peterson LR, Ferguson RM: Fatal central nervous system infection with varicellazoster virus in renal transplant recipients. Transplantation 1984; 37: 366-368.
23. Herrero JI, Quiroga J, Sangro B, Pardo F, Rotellar F, Alvarez-Cienfuegos J, Prieto J: Herpes zoster after liver transplantation: Incidence, risk factors, and complications. Liver Transpl 2004; 10: 1140-1143.
24. Litjens NH, Huisman M, Baan CC, van Druningen CJ, Betjes MG: Hepatitis B vaccine- specific CD4+ T cells can be detected and characterised at the single cell level: Limited usefulness of dendritic cells as signal enhancers. J Immunol Methods 2008; 330: 1-11.
25. Crosnier J: Hepatitis B in haemodialysis: Vaccination against HBS antigen. Proc Eur Dial Transplant Assoc 1981; 18: 231-240.